Supernus Sues Ingenus to Block Copies of Oxtellar Seizure Drug

Supernus said a generic version of Oxtellar XR proposed by closely held Ingenus Pharmaceuticals infringes nine patents for the drug, used to treat partial seizures.

• Supernus is seeking court order blocking copies until patents have expired and cash compensation if copies are made before then, according to complaint filed Thursday in federal court in Trenton, New Jersey
• Patents expire in April 2027: FDA Orange Book
• Supernus in June 2020 filed lawsuit accusing Apotex of infringing same patents; that case, also in New Jersey, is pending
• CASE: Supernus Pharmaceuticals Inc. v. RiconPharma LLC, 3:21-cv-12133, U.S. District Court, District of ...